Drug Trial Radar · NCT05785741
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Apr 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,000
Planned (sponsor's estimate)
Start
Aug 17, 2023
Primary completion
Dec 30, 2027
Study completion Apr 30, 2028
Sponsor
- Lead sponsor
- DualityBio Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 27, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.
Conditions
- Advanced Solid Tumor
Interventions
DB-1310Drug
Administered I.V.
TrastuzumabDrug
Administered I.V.
OsimertinibDrug
Oral
capecitabineDrug
Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Percentage of Participants with Dose-Limiting Toxicities (DLTs) as assessed by CTCAE v5.0. Percentage of participants in Part 1 with DLTsTime frame: up to 21 days after Cycle 1 Day 1
- Phase 1: Percentage of Participants with Treatment Emergent Adverse Events (TEAEs) as assessed by CTCAE v5.0.Time frame: Up to follow-up period, approximately 1 year post-treatment
- Phase 1: Percentage of Participants with Serious Adverse Events (SAEs) as assessed by CTCAE v5.0.Time frame: Up to follow-up period, approximately 1 year post-treatment
- Maximum Tolerated Dose (MTD) of DB-1310Time frame: 12 months
- Phase 1: Recommended Phase 2 Dose (RP2D) of DB-1310Time frame: 12 months
- Phase 2a: Percentage of Participants with Treatment Emergent adverse events (TEAEs) as assessed by CTCAE v5.0.Time frame: Up to follow-up period, approximately 1 year post-treatment
- Phase 2a: Percentage participants with Serious Adverse Events (SAEs) as assessed by CTCAE v5.0.Time frame: Up to follow-up period, approximately 1 year post-treatment
- Phase 2a: Percentage of Objective Response Rate (ORR) as assessed by RECIST 1.1.Time frame: Up to follow-up period, approximately 1 year post-treatment
Locations
24 sites in 2 countries. Site status is shown where the registry gives one.
University of California, Davis Comprehensive Cancer Center
Sacramento, California · Recruiting
UCLA Hematology/Oncology - Santa Monica
Santa Monica, California · Recruiting
Research Site 117
Coral Gables, Florida · Withdrawn
D&H Cancer Research Center LLC
Margate, Florida · Withdrawn
Sarah Cannon Research Institute at Florida Cancer Specialists
Orlando, Florida · Recruiting
BRCR global
Plantation, Florida · Recruiting
Florida Cancer Specialists
Sarasota, Florida · Recruiting
BRCR Medical Center Inc.
Tamarac, Florida · Recruiting
Research Site 111
Atlanta, Georgia · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Henry Ford Health System
Detroit, Michigan · Recruiting
Research site 119
Florham Park, New Jersey · Active not recruiting
Carl & Edyth Lindner Center for Research & Education at The Christ Hospital and The Christ Hospital Cancer Center
Cincinnati, Ohio · Recruiting
Tennessee Oncology, PLLC
Nashville, Tennessee · Recruiting
NEXT Virginia
Fairfax, Virginia · Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Hunan cancer hospital
Changsha, Hunan, China · Recruiting
Jiangsu Province hospital
Nanjing, Jiangsu, China · Recruiting
Affiliated Hospital of Jiangnan University
Wuxi, Jiangsu, China · Recruiting
The first hospital of Jilin University
Changchun, Jilin, China · Recruiting
The First Hospital of China Medical University
Shenyang, Liaoning, China · Recruiting
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China · Recruiting
Research Site 222
Chengdu, Sichuan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.